

Pharmaceutical Test Data Exclusivity

A Multi-Jurisdictional Survey

AIPPI Law Series

VOLUME 7

Series Editors

AIPPI

Introduction & Contents/Subjects

Books in this series are developed within the framework of the International Association for the Protection of Intellectual Property (AIPPI), a non-affiliated non-profit organization dedicated to the development and improvement of legal regimes for the protection of intellectual property at both national and international levels.

Objective & Readership

The aim is to publish innovative work appealing to practitioners, other users of IP systems and academics.

The titles in this series are listed at the back of this volume.

Pharmaceutical Test Data Exclusivity

A Multi-Jurisdictional Survey

Edited by

John C. Todaro

Martin Bensadon

Brigitte Carion-Taravella



Wolters Kluwer

Published by:

Kluwer Law International B.V.

PO Box 316

2400 AH Alphen aan den Rijn

The Netherlands

E-mail: lrs-sales@wolterskluwer.com

Website: www.wolterskluwer.com/en/solutions/kluwerlawinternational

Sold and distributed by:

Wolters Kluwer Legal & Regulatory U.S.

7201 McKinney Circle

Frederick, MD 21704

United States of America

Email: customer.service@wolterskluwer.com

Printed on acid-free paper.

ISBN 978-94-035-0106-2

e-Book: ISBN 978-94-035-0136-9

web-PDF: ISBN 978-94-035-0146-8

AIPPI Law Series ISBN 98-888-8020-8

© 2022 Kluwer Law International BV, The Netherlands

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Permission to use this content must be obtained from the copyright owner. More information can be found at: www.wolterskluwer.com/en/solutions/legal-regulatory/permissions-reprints-and-licensing.

Printed in the United Kingdom.

Table of Contents

List of Contributors	v
List of Abbreviations	xxv
Foreword	xxvii
<i>Luiz Henrique do Amaral, President of AIPPI</i>	
Introduction	1
<i>John C. Todaro, Martin Bensadon, Brigitte Carion-Taravella</i>	
Argentina	5
<i>Martín Bensadon, Eugenio Hoss</i>	
1. General Legal Rules and Regulatory Data Protection Availability	5
a) Pharmaceutical Products	5
b) Other Products (Agricultural, Animal Health)	6
2. Requirements for Protection	6
a) Substantive Requirements	6
b) Formal Requirements	6
3. Scope of Protection	6
a) Confidentiality	6
b) Prevention to Reference or Rely on Data	7
c) Market Exclusivity or Other Rights	7
4. Regulatory Data Protection Grant and Enforcement in Practice	7
Australia	9
<i>Nicholas Tyacke, Eliza Saunders, Sarah McKenzie</i>	
1. General Legal Rules and Regulatory Data Protection Availability	9
a) Pharmaceutical Products	9
i) Chemical Products	9
ii) Biological Products	10
iii) Orphan Drugs	10
iv) New Uses or Formulations	10

v) Product Combinations	10
vi) Approvals or Testing for Paediatrics Products	10
b) Other Products (Agricultural, Animal Health)	10
2. Requirements for Protection	11
a) Substantive Requirements	11
b) Formal Requirements	12
3. Scope of Protection	12
a) Confidentiality	12
b) Prevention to Reference or Rely on Data	12
c) Market Exclusivity or Other Rights	12
4. Regulatory Data Protection Grant and Enforcement in Practice	13
Brazil	15
<i>Ana Claudia Mamede Carneiro, Roberto Faria de Sant'Anna Junior</i>	
1. General Legal Rules and Regulatory Data Protection Availability	15
a) Pharmaceutical Products	15
b) Other Products (Agricultural, Animal Health)	15
2. Requirements for Protection	16
a) Substantive Requirements	16
b) Formal Requirements	16
3. Scope of Protection	16
a) Confidentiality	16
b) Prevention to Reference or Rely on Data	17
c) Market Exclusivity or Other Rights	17
4. Regulatory Data Protection Grant and Enforcement in Practice	18
Canada	19
<i>Charles Boulakia, Santosh Chari, Anita Nador</i>	
1. General Legal Rules and Regulatory Data Protection Availability	19
a) Pharmaceutical Products	20
i) Chemical Products	20
ii) Biological Products	20
iii) Orphan Drugs	21
iv) New Uses or Formulations	21
v) Product Combinations	21
vi) Approvals or Testing for Pediatrics Products	21
b) Other Products (Agricultural, Animal Health)	21
2. Requirements for Protection	22
a) Substantive Requirements	22
b) Formal Requirements	23
3. Scope of Protection	23
a) Confidentiality	23
b) Prevention to Reference or Rely on Data	24
c) Market Exclusivity or Other Rights	24
4. Regulatory Data Protection Grant and Enforcement in Practice	24

Chile	25
<i>Ignacio Gillmore, José Santos Ossa, Camila Suarez Alcántara</i>	
1. General Legal Rules and Regulatory Data Protection Availability	25
a) Pharmaceutical Products	26
i) Chemical Products	26
ii) Biological Products	26
iii) Orphan Drugs	26
iv) New Uses or Formulations	27
v) Product Combinations	27
vi) Approvals or Testing for Pediatrics Products	27
b) Other Products (Agricultural/Animal Health)	27
2. Requirements for Protection	28
a) Substantive Requirements	28
i) Undisclosed Data	28
ii) New Chemical Entity	29
b) Formal Requirements	30
3. Scope of Protection	30
4. Regulatory Data Protection Grant and Enforcement in Practice	31
China	33
<i>Amy Feng, Alex Guan</i>	
1. General Legal Rules and Regulatory Data Protection Availability	33
a) Pharmaceutical Products	35
b) Other Products (Agricultural, Animal Health)	35
2. Requirements for Protection	35
a) Substantive Requirements	35
b) Formal Requirements	35
3. Scope of Protection	35
a) Confidentiality	35
b) Prevention to Reference or Rely on Data	36
c) Market Exclusivity or Other Rights	36
i) Paediatrics Drugs	36
ii) Orphan Drugs	36
iii) First Chemical Generic Drugs with Successful Patent Challenge	36
4. Regulatory Data Protection Grant and Enforcement in Practice	37
Colombia	39
<i>Ximena Castellanos</i>	
1. General Legal Rules and Regulatory Data Protection Availability	39
a) Pharmaceutical Products	40
i) Chemical Products	41
ii) Biological Products	41
iii) Orphan Drugs	41
iv) New Uses or Formulations	41
v) Product Combinations	41
vi) Approvals or Testing for Pediatric Products	41
b) Other Products (Agricultural, Animal Health)	41

2.	Requirements for Protection	41
	a) Substantive Requirements	41
	b) Formal Requirements	42
3.	Scope of Protection	42
	a) Confidentiality	42
	b) Prevention to Reference or Rely on Data	42
	c) Market Exclusivity or Other Rights	43
4.	Regulatory Data Protection Grant and Enforcement in Practice	43

European Union 45

Mathilde Rauline, Muriel Morel-Pécheux, Maurane Cadinot, Nicolás Vincent Ruiz, Brigitte Carion-Taravella

1.	General Legal Rules and Regulatory Data Protection Availability	45
	a) Pharmaceutical Products	46
	i) Chemical Products	46
	ii) Biological Products	46
	iii) Orphan Drugs	46
	iv) New Uses or Formulations	46
	v) Product Combinations	47
	vi) Approvals or Testing for Paediatrics Products	48
	b) Other Products (Agricultural, Animal Health)	48
2.	Requirements for Protection	49
	a) Substantive Requirements	49
	b) Formal Requirement	50
3.	Scope of Protection	51
	a) Confidentiality	51
	b) Prevention to Reference or Rely on Data	51
	c) Market Exclusivity or Other Rights	51
4.	Regulatory Data Protection Grant and Enforcement in Practice	51

India 53

Vidisha Garg

1.	General Legal Rules and Regulatory Data Protection Availability	53
	a) Pharmaceutical Products	53
	i) Chemical Products	53
	ii) Biological Products	54
	iii) Orphan Drugs	54
	iv) New Uses or Formulations	55
	v) Product Combinations	55
	vi) Approvals or Testing for Paediatrics Products	55
	b) Other Products (Agricultural, Animal Health)	55
2.	Requirements for Protection	55
3.	Scope of Protection	55
4.	Regulatory Data Protection Grant and Enforcement in Practice	55

Israel	57
<i>David Gilat</i>	
1. General Legal Rules and Regulatory Data Protection Availability	57
2. Requirements for Protection	57
3. Scope of Protection	58
a) Confidentiality	58
b) Prevention to Reference or Rely on Data	58
4. Regulatory Data Protection Grant and Enforcement in Practice	59
Japan	61
<i>Takeshi S. Komatani, Takashi Fujita, Osamu Yamamoto, Yoshinori Shimizu, Masaru Nakajima</i>	
1. General Legal Rules and Regulatory Data Protection Availability	61
a) Pharmaceutical Products	61
b) Other Products (Agricultural, Animal Health)	64
2. Requirements for Protection	65
3. Scope of Protection	65
a) Confidentiality	65
b) Prevention to Reference or Rely on Data	66
c) Market Exclusivity or Other Rights	66
4. Regulatory Data Protection Grant and Enforcement in Practice	66
Republic of Korea	67
<i>Yoon Suk Shin</i>	
1. General Legal Rules and Regulatory Data Protection Availability	67
a) Pharmaceutical Products	67
i) Chemical Products	67
ii) Biological Products	68
iii) Orphan Drugs	68
iv) New Uses or Formulations	68
v) Product Combinations	68
vi) Approvals or Testing for Paediatrics Products	68
b) Other Products (Agricultural, Animal Health)	68
2. Requirements for Protection	69
a) Substantive Requirements	69
b) Formal Requirements	70
3. Scope of Protection	70
a) Confidentiality	70
b) Prevention to Reference or Rely on Data	70
c) Market Exclusivity or Other Rights	70
4. Regulatory Data Protection Grant and Enforcement in Practice	70
Mexico	71
<i>Carolina Ponce</i>	
1. General Legal Rules and Regulatory Data Protection Availability	71
2. Requirements for Protection	72
3. Scope of Protection	72

a) Confidentiality	72
b) Prevention to Reference or Rely on Data	72
c) Market Exclusivity or Other Rights	72
4. Regulatory Data Protection Grant and Enforcement in Practice	72
Peru	73
<i>Carlos Fernández-Dávila Winkler, Julisa Quiliche Chávez, Nicolle Pérez Mercado</i>	
1. General Legal Rules and Regulatory Data Protection Availability	73
a) Pharmaceutical Products	73
i) Chemical Products	74
ii) Biological Products	75
iii) Orphan Drugs	75
iv) New Uses or Formulations	76
v) Product Combinations	76
vi) Approvals or Testing for Pediatrics Products	76
b) Other Products (Agricultural, Animal Health)	76
2. Requirements for Protection	77
a) Substantive Requirements	77
i) The Test Data or Other Undisclosed Data Shall Involve Considerable Effort	77
ii) The Test Data or Other Undisclosed Data Shall Relate to Pharmaceutical and Agrochemical Products that Include New Chemical Entities	78
iii) The Test Data Shall Not Be Disclosed to the Public Before the Protection Application	79
b) Formal Requirements	79
i) Pharmaceutical Products	79
ii) Agrochemical Products	80
3. Scope of Protection	80
a) Confidentiality	80
b) Prevention to Reference or Rely on Data	81
c) Market Exclusivity or Other Rights	81
4. Regulatory Data Protection Grant and Enforcement in Practice	81
Russia	83
<i>Renat Krasnoperov</i>	
1. General Legal Rules and Regulatory Data Protection Availability	83
a) Pharmaceutical Products	83
2. Requirements for Protection	83
3. Scope of Protection	84
a) Confidentiality	84
b) Prevention to Reference to Rely on Data	84
c) Market Exclusivity or Other Rights	85
4. Regulatory Data Protection Grant and Enforcement in Practice	85

Kingdom of Saudi Arabia	87
<i>Namir B. Sioufi</i>	
1. General Legal Rules and Regulatory Data Protection Availability	87
a) Pharmaceutical Products	87
i) Chemical Products	87
ii) Biological Products	87
iii) Orphan Drugs	88
iv) New Uses or Formulations	88
v) Product Combinations	88
vi) Approvals or Testing for Pediatrics Products	88
b) Other Products (Agricultural, Animal Health)	88
2. Requirements for Protection	88
a) Substantive Requirements	88
b) Formal Requirements	88
3. Scope of Protection	89
a) Confidentiality	89
b) Prevention to Reference or Rely on Data	89
c) Market Exclusivity or Other Rights	89
4. Regulatory Data Protection Grant and Enforcement in Practice	90
South Africa	93
<i>Dirk Hanekom</i>	
1. General Legal Rules and Regulatory Data Protection Availability	93
a) Pharmaceutical Products	94
b) Other Products (Agricultural, Animal Health)	94
2. Requirements for Protection	94
a) Substantive Requirements	94
b) Formal Requirements	94
3. Scope of Protection	94
a) Confidentiality	94
b) Prevention to Reference or Rely on Data	94
c) Market Exclusivity or Other Rights	95
4. Regulatory Data Protection Grant and Enforcement in Practice	95
Switzerland	97
<i>Simon Holzer</i>	
1. General Legal Rules and Regulatory Data Protection Availability	97
a) Pharmaceutical Products	97
i) Chemical Products	97
ii) Biological Products	99
iii) Orphan Drugs	99
iv) New Uses or Formulations	99
v) Product Combinations	100
vi) Approvals or Testing for Pediatrics Products	100
b) Other Products (Agricultural, Animal Health)	100
2. Requirements for Protection	101
a) Substantive Requirements	101

b) Formal Requirements	101
3. Scope of Protection	102
a) Confidentiality	102
b) Prevention to Reference or Rely on Data	102
c) Market Exclusivity or Other Rights	102
4. Regulatory Data Protection Grant and Enforcement in Practice	103
Taiwan	105
<i>Kevin C.W. Feng</i>	
1. General Legal Rules and Regulatory Data Protection Availability	105
a) Pharmaceutical Products	105
b) Other Products (Agricultural, Animal Health)	107
2. Requirements for Protection	107
a) Substantive Requirements	107
b) Formal Requirements	108
3. Scope of Protection	108
a) Confidentiality	108
b) Prevention to Reference or Rely on Data	108
c) Market Exclusivity or Other Rights	108
4. Regulatory Data Protection Grant and Enforcement in Practice	109
Turkey	111
<i>Ezgi Baklacı Gülkökar</i>	
1. General Legal Rules and Regulatory Data Protection Availability	111
a) Pharmaceutical Products	111
i) Chemical Products	112
ii) Biological Products	112
iii) Orphan Drugs	112
iv) New Uses or Formulations	112
v) Product Combinations	113
vi) Approvals or Testing for Pediatrics Products	113
b) Other Products (Agricultural, Animal Health)	113
2. Requirements for Protection	114
a) Substantive Requirements	114
b) Formal Requirements	114
3. Scope of Protection	114
a) Confidentiality	114
b) Prevention to Reference or Rely on Data	115
c) Market Exclusivity or Other Rights	115
4. Regulatory Data Protection Grant and Enforcement in Practice	115
United Arab Emirates	117
<i>Namir B. Sioufi</i>	
1. General Legal Rules and Regulatory Data Protection Availability	117
a) Pharmaceutical Products	117
i) Chemical Products	117
ii) Biological Products	118

iii) Orphan Drugs	118
iv) New Uses or Formulations	118
v) Product Combinations	118
vi) Approvals or Testing for Pediatrics Products	118
b) Other Products (Agricultural, Animal Health)	118
2. Requirements for Protection	119
a) Substantive Requirements	119
b) Formal Requirements	119
3. Scope of Protection	119
a) Confidentiality	119
b) Prevention to Reference or Rely on Data	120
c) Market Exclusivity or Other Rights	120
4. Regulatory Data Protection Grant and Enforcement in Practice	120
United Kingdom	123
<i>Daniel Lim</i>	
1. General Legal Rules and Regulatory Data Protection Availability	123
a) Pharmaceutical Products	124
b) Other Products (Agricultural, Animal Health)	125
2. Requirements for Protection	126
3. Scope of Protection	126
4. Regulatory Data Protection Grant and Enforcement in Practice	126
United States	127
<i>Michael K. Stern</i>	
1. General Legal Rules and Regulatory Data Protection Availability	127
a) Pharmaceutical Products	127
i) Chemical Products	127
ii) Biological Products	129
iii) Orphan Drugs	130
iv) New Uses or Formulations	130
v) Product Combinations	131
vi) Approvals or Testing for Pediatric Products	131
b) Other Products (Agricultural, Animal Health)	132
2. Requirements for Protection	133
a) Substantive Requirements	133
i) New Chemical Entity Exclusivity	133
ii) New Clinical Investigation Exclusivity	133
iii) Orphan-Drug Exclusivity	134
iv) Qualified Infectious Disease Product Exclusivity	134
v) Reference Product Exclusivity	135
vi) Pediatric Exclusivity	135
vii) Animal Drugs	136
viii) Pesticides	136
b) Formal Requirements	137
i) Human Drug and Biological Products	137
ii) Animal Health Products	138

iii) Pesticides	138
3. Scope of Protection	139
a) Confidentiality	139
i) Drug and Biological Products	139
ii) Pesticides	139
b) Prevention to Reference or Rely on Data	140
i) New Chemical Entity Exclusivity	140
ii) New Clinical Investigation Exclusivity	140
iii) Reference Product Exclusivity	141
iv) Pediatric Exclusivity	141
v) Qualified Infectious Disease Product Exclusivity	141
vi) Animal Drugs	141
vii) Pesticides	142
c) Market Exclusivity or Other Rights	142
i) New Clinical Investigation Exclusivity	142
ii) Orphan-Drug Exclusivity	143
iii) Pediatric Exclusivity	144
iv) Qualified Infectious Disease Product Exclusivity	144
v) Animal Drugs	144
4. Regulatory Data Protection Grant and Enforcement in Practice	144

Switzerland

Simon Holzer

1. GENERAL LEGAL RULES AND REGULATORY DATA PROTECTION AVAILABILITY

Switzerland is an important research location for the pharmaceutical industry. It is therefore no surprise that Switzerland has set up a comprehensive system to protect the results of pharmaceutical research.

The basis of the Swiss efforts for the protection of data filed for the authorization of pharmaceutical products is Article 39(3) of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). The Swiss provisions on regulatory data protection go far beyond the TRIPS minimum requirements.

Specific regulations on providing regulatory data protection to the technical data generated by innovator companies for the marketing authorizations of their preparations, i.e., data generated by drug firms through preclinical and clinical trials to prove the efficacy and safety of their products, were introduced in the Federal Medicinal Products and Medical Devices Act of 15 December 2000.

On 1 January 2019, revised provisions for the protection of data filed in support of marketing authorization applications for pharmaceutical products came into force in Switzerland. In principle, these new provisions also apply to products that were already approved before 1 January 2019, except for the special rules on orphan drugs, pediatric uses and regulatory data protection for new indications with a significant clinical benefit proven by extensive clinical trials. These provisions only apply to products filed for registration after 1 January 2019.

a) Pharmaceutical Products

i) Chemical Products

Documents filed in support of marketing authorizations for human medicinal products comprising at least one new active substance or dossiers for new indications, new dosage recommendations, new modes of administration, orphan drugs or pediatric

uses, i.e., the pharmacological, toxicological and clinical trial data for such marketing authorizations, are protected from use and reference by third parties (regulatory data protection).

The following laws are relevant for the regulatory data protection of human health products in Switzerland:

- Federal Medicinal Products and Medical Devices Act of 15 December 2000 (Therapeutic Product Act, SR 812.21)
- Federal Ordinance on Medicinal Products of 21 September 2018 (Medicinal Products Ordinance, SR 812.212.21)

The Swiss regulatory data protection regulations provide for a total regulatory data protection period of ten years for data filed in support of marketing authorization applications for medicinal products for human health with at least one new active substance. According to the definition of the Therapeutic Product Act, a new active substance means an active substance which is authorized for the first time in Switzerland pursuant to an ordinary marketing authorization procedure under the Therapeutic Product Act. Active substances previously only authorized in medicinal products for human use shall be considered new active substances if they are used in products for veterinary use, and vice versa.

This ten-year regulatory data protection period for new active substances consists of an initial data exclusivity period of eight years and an additional market exclusivity of two years for the corresponding product.

During the initial data exclusivity period, the data submitted to the Swiss Agency for Therapeutic Products (Swissmedic) in support of a Swiss marketing authorization for a product comprising at least one new active substance is protected from being referenced by later filed marketing authorization applications (data exclusivity).

During the last two years of the regulatory data protection period, third parties might refer to the protected data submitted in support of older marketing authorizations for marketing authorization applications for generic products or biosimilars. However, Swissmedic may only grant a marketing authorization for the new generic product or biosimilar on the first day after the end of the total regulatory data protection period (market exclusivity).

The data filed in support of a Swiss marketing authorization for a medicinal product that contains no new active substance but concerns a new indication, new mode of administration, or new dosage form is protected for a separate period of three years after the grant of the new marketing authorization or the amendment of an existing marketing authorization. This regulatory data protection period for new indications, new modes of administration, or new dosage forms runs independently of the aforementioned ten-year protection for the main dossier that covers at least one new active substance.

For new indications of known active substances that are expected to bring a significant clinical benefit in comparison with existing therapies and that are based on extensive clinical trials, the regulatory data protection period will be extended by Swissmedic to up to ten years upon applicant's request.

In addition, Swissmedic grants, on the applicant's request, a total data protection period of ten years for medicinal products specifically and exclusively for pediatric use in accordance with the pediatric investigation plan of those products, provided

that no data protection exists for another medicinal product authorized by Swissmedic with the same active substance for the same specific pediatric use.

In summary, Swiss law provides for a general data protection period of 8 + 2 years following the grant of the marketing authorization for dossiers filed in support of marketing authorization applications for medicinal products with at least one new active substance (i.e. eight-year data exclusivity and two-year market exclusivity, similar to the solution of the EU). Apart from that, the regulatory data protection regime in Switzerland differs considerably from the EU regulations. In particular, dossiers for new indications, new modes of administration, new dosage forms or dosages, or new applications to new target animal species benefit from a separate data protection period that is independent from the data protection period for the data filed in support of the initial marketing authorization application.

If, exceptionally, the separate data protection period for the data that supports a marketing application for a new indication, new mode of administration, new dosage form or dosage, or an application for a new target animal species expires before the regulatory data protection period of the documents filed for the initial marketing authorization, third parties cannot simply make use of or refer to the data filed in support of the new indication, etc., immediately but only after the expiry of the 8 + 2 regulatory data protection period of the data for the initial marketing authorization (provided that the initial marketing authorization enjoyed a ten-year regulatory data protection period). This is because a reference to the documents filed in support of the new indication, etc., is not sufficient for the grant of a marketing authorization but it also requires a reference to the dossier of the basic application.

ii) Biological Products

Swiss regulatory data protection as described above for chemical compounds also applies to biological products. The ten-year standard regulatory data protection is only available to new biological products that are authorized based on a complete dossier. Similar to chemical compounds, the data filed in support of a new indication, new mode of administration, new dosage form or dosage of a biological product enjoys a separate data protection period that runs independently from the data exclusivity period for the main dossier.

iii) Orphan Drugs

The new provisions of the Therapeutic Product Act on regulatory data protection in force since 2019 provide fifteen years of regulatory data protection for medicinal products with orphan drug status or 'minor use or minor species'. This regulatory data protection is only available if these marketing authorization applications were received by Swissmedic on or after 1 January 2019.

iv) New Uses or Formulations

As explained above, Swiss regulatory data protection also applies to new uses of previously approved drugs. The data filed in support of a Swiss marketing authorization

for a human health or animal health medicinal product that contains no new active substances is still protected for a period of three years, if the data are filed in support of a new indication, new mode of administration, new dosage form or dosage, or an application to a new target animal species.

For new indications that are expected to bring a significant clinical benefit in comparison with existing therapies and that are based on extensive clinical trials, the regulatory data protection period is ten years.

v) *Product Combinations*

Generally, regulatory data protection only applies to medicinal products with at least one new active substance.

If a combination product does not contain at least one new active substance, it only benefits from regulatory data protection if the combination concerns a new indication, new mode of administration, or new dosage form or dosage or if the medicinal product is specifically and exclusively for pediatric use or an orphan drug.

vi) *Approvals or Testing for Pediatrics Products*

Swissmedic grants, on the applicant's request, a data protection period of ten years for the data of medicinal products specifically and exclusively for pediatric use in accordance with the pediatric investigation plan of those products, provided that no data protection exists for another medicinal product authorized by Swissmedic with the same active substance(s) for the same pediatric use.

A product for purely pediatric use can also be an essentially identical medicinal product (for example a known active substance or biosimilar) and still enjoy ten years of regulatory data protection. However, Swissmedic only grants the ten-year regulatory data protection for pediatric uses if the submitted studies / investigations in relation to the product correspond with the pertinent pediatric investigation plan.

Pharmaceutical companies should note that this type of regulatory data protection is granted only for medicinal products that are intended specifically and exclusively for pediatric use. The medicinal product may not have an additional indication for adults. If a pharmaceutical company plans to use the same active substance in adults, it must do so with a separate medicinal product (separate product name, separate authorization, etc.) if it does not want to jeopardize the regulatory data protection for its pediatric product in Switzerland.

b) *Other Products (Agricultural, Animal Health)*

The regulatory data protection described above also applies to animal health products. This means that there is a ten-year data protection period (eight years of data exclusivity and another two years of market exclusivity) for animal health products and a three- to ten-year regulatory data protection period for new indications, new modes of administration, or new dosage forms or dosages. Furthermore, there is a three-year regulatory data protection period for the dossier of an application to new target animal species.

The Swiss Federal Ordinance on the Placing of Plant Protection Products on the Market (Ordinance on Plant Protection Products, SR 916.161) further stipulates that tests and study reports on the active substance of plant protection products (pesticides), safeners or synergists, additives or on the concerned plant protection product submitted to the Swiss Federal Office of Agriculture for the authorization of a plant protection product cannot be used for the grant of an authorization or amendment for another product for a period of ten years from the date of the first authorization of the plant protection product. This period is extended to thirteen years for tests and study reports filed in support of authorizations for low-risk plant protection products. The Ordinance on Plant Protection Products provides for additional extensions and exceptions. The total period of protection for normal plant protection products shall in no case exceed thirteen years; for low-risk plant protection products, the total term of protection shall not exceed fifteen years. Subject to certain exceptions, experimental dossiers and study reports that are required for the renewal or review of an existing authorization are normally protected for a period of thirty months. Special provisions apply to data concerning tests on vertebrate animals. Generally, the applicant of a later filed marketing authorization can refer to such data but must pay a reasonable royalty so that the animal experiments do not have to be carried out at all, if possible. If the parties cannot agree on the royalty rate, the Federal Office of Agriculture takes a decision and fixes the royalty rate.

2. REQUIREMENTS FOR PROTECTION

a) Substantive Requirements

As mentioned above, specific regulatory data protection periods are available for (i) new active substances, (ii) new indications of known active substances, (iii) new modes of administration, (iv) new dosage forms or dosages, (v) applications to a new target animal species, (vi) orphan drugs and minor use or minor species status products, (vii) pediatric use products, and (viii) certain data filed in support of plant protection products.

b) Formal Requirements

The ten-year regulatory data protection period for medicinal products with new active substances and the three-year regulatory data protection period for new indications, new modes of administration, new dosage forms or dosages, or applications to new target animal species is automatically taken into account and granted by Swissmedic and does not require an application or specific evidence.

Additional regulatory data protection for the data filed in support of a special marketing authorization application is only available upon explicit request of the applicant and requires the submission of pertinent evidence or at least arguments.

If a product qualifies for regulatory data protection, then Swissmedic explicitly mentions the total duration of the regulatory data protection period in each new marketing authorization or in the amendment of an existing marketing authorization.

There are no specific preconditions to be observed if an applicant wants to obtain regulatory data protection. For example, Swiss regulatory data exclusivity is not dependent on filing for marketing approval within a certain time period relative to filing for marketing approval abroad.

3. SCOPE OF PROTECTION

a) Confidentiality

Generally, no data submitted to Swissmedic for obtaining a marketing authorization for a medicinal product will be disclosed to third parties.

The Swiss provisions concerning regulatory data protection regulate at what point in time third parties wishing to authorize a generic or biosimilar product may refer to the data submitted in support of an older marketing authorization application of an original product or reference product.

In addition, Swiss law not only stipulates when such reference is possible, but also the earliest point in time when Swissmedic may grant a marketing authorization for a product that makes reference to the dossier of another product.

According to the practice of the Swiss Federal Data Protection and Information Commissioner, under certain circumstances third parties may have a right to access the documents filed in support of a marketing authorization for a medicinal product under the Swiss Freedom to Information Act (see for example the recommendation of the Swiss Federal Data Protection and Information Commissioner dated 30 March 2010). However, trade secrets and manufacturing secrets are not to be disclosed. Since most of the studies submitted to Swissmedic concern trade secrets and/or manufacturing secrets, large parts of a dossier submitted to Swissmedic will therefore not be available to third parties even under the Freedom of Information Act.

b) Prevention to Reference or Rely on Data

As mentioned above, it is not possible to make reference to data that still enjoys data exclusivity. According to Swiss law, the data exclusivity period ends two years prior to the total regulatory data protection period. If a third party files a marketing authorization application with Swissmedic prior to the expiry of the data exclusivity period, then Swissmedic dismisses such application without prejudice and the application must be refiled at a later date.

c) Market Exclusivity or Other Rights

During the last two years of the total regulatory data protection period, Swissmedic may examine new applications that refer to protected data but the marketing authorization for the new product may only be granted after the expiry of the total regulatory data protection period. This means that during the last two years of the total regulatory data protection period, the protected data and dossiers no longer benefit from strict data exclusivity, but from market exclusivity only.

According to Swissmedic, the distinction between the data exclusivity period and the two-year market exclusivity period at the end of the total regulatory data protection period only applies to regulatory data protection periods of ten years and longer. This means, for example, that according to Swissmedic, a marketing authorization application for an indication of a known active substance that still enjoys separate regulatory data protection (e.g., three years for a new indication) can only be filed on the first day after the total regulatory data protection period has expired. This practice seems to conflict with the clear language of the law that says that an application for marketing authorization may be submitted two years before the end of the term of the regulatory data protection period. There is no case law available at this stage that would clarify this issue.

4. REGULATORY DATA PROTECTION GRANT AND ENFORCEMENT IN PRACTICE

The regulatory data protection period for a veterinary or human medicinal product is mentioned in the grant of the marketing authorization for the concerned product.

If the applicant that filed the marketing authorization application disagrees with the duration or refusal of the regulatory data protection period by Swissmedic, this part of Swissmedic's marketing authorization can be appealed to the Swiss Federal Administrative Court.

Swissmedic publishes a list with all veterinary and human medicinal products that enjoy regulatory data protection in Switzerland. This list has just under 800 entries (as of April 2022) including new active substances, new indications, new modes of administration, new dosage forms or dosages, new applications to a new target animal species, new orphan drugs, and new pediatric uses.